SCHEMBL4718463

SCHEMBL4718463

CCOC(=O)c1cc2c(ccc(=O)n2-c2ccccc2[N+](=O)[O-])n1Cc1cccc(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
TDP1 Q9NUW8 5/20 0.45
KDM4E B2RXH2 3/20 0.45
MAPK1 P28482 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.43
POLB P06746 2/20 0.43
ATM Q13315 1/20 0.43
BRD4 O60885 2/20 0.42
NOD2 Q9HC29 1/20 0.42
NOD1 Q9Y239 1/20 0.42
F10 P00742 3/20 0.41
RECQL P46063 2/20 0.41
CCR2 P41597 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4712174 0.84 MAPT (0.51) MAPTTDP1KDM4EMAPK1NPSR1
SCHEMBL4716291 0.81 NOD2 (0.52) MAPTTDP1KDM4EMAPK1NPSR1
SCHEMBL4649521 0.81 CCR2 (0.58) MAPTTDP1KDM4EMAPK1NPSR1
SCHEMBL4714118 0.78 MAPT (0.47) MAPTTDP1KDM4EMAPK1NPSR1
SCHEMBL4716102 0.77 MAPT (0.57) MAPTTDP1KDM4EMAPK1NPSR1
SCHEMBL4716301 0.76 MAPT (0.44) MAPTTDP1KDM4EMAPK1NPSR1
SCHEMBL4789434 0.74 ALDH1A1 (0.53) MAPTTDP1KDM4EMAPK1NPSR1
SCHEMBL4653080 0.74 F10 (0.45) MAPTTDP1KDM4EMAPK1NPSR1
SCHEMBL6307843 0.73 NOD2 (0.74) MAPTTDP1KDM4EMAPK1NPSR1
SCHEMBL4650061 0.73 KMT2A (0.44) MAPTTDP1KDM4EMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 MAPT 1831/4885TDP1 983/4885KDM4E 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.